Boxer Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Boxer Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,611	Closed	-$1.52M	–	29
2017 Q3	$1.52M	Hold	4,611	–	–	0.35%	26
2017 Q2	$1.09M	Hold	4,611	–	–	0.26%	25
2017 Q1	$1.58M	Hold	4,611	–	–	0.35%	24
2016 Q4	$1.61M	Hold	4,611	–	–	0.62%	19
2016 Q3	$1.85M	Buy	4,611 +1,500	+48%	+$765K	0.83%	21
2016 Q2	$1.85M	Hold	3,111	–	–	1.64%	16
2016 Q1	$1.56M	Hold	3,111	–	–	1.53%	16
2015 Q4	$2.06M	Buy	+3,111	New	+$1.76M	1.78%	9

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital's EIGR Position: Q4 2017 in Review

Boxer Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2017, closing a stake of 4,611 shares — an estimated $1.52M sold.

Boxer Capital first reported a position in EIGR in Q4 2015 and held it in 8 quarters. The position peaked at $2.06M in Q4 2015. 40 funds tracked by Wall St. Rank hold EIGR as of Q4 2017.

Boxer Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Boxer Capital sold 4,611 Eiger BioPharmaceuticals, Inc. shares in Q4 2017, an estimated $1.52M.
Boxer Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 8 quarters.
Boxer Capital's Eiger BioPharmaceuticals, Inc. position peaked at $2.06M in Q4 2015.
40 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2017.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.